We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genflow Biosciences plc (GENF) ORD GBP0.0003

Sell:2.10p Buy:2.20p 0 Change: 0.1p (4.44%)
Market closed |  Prices as at close on 13 September 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.10p
Buy:2.20p
Change: 0.1p (4.44%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 13 September 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.10p
Buy:2.20p
Change: 0.1p (4.44%)
Market closed |  Prices as at close on 13 September 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.

Contact details

Address:
6 Heddon Street
LONDON
W1B 4BT
United Kingdom
Telephone:
+ (0)
Website:
https://genflowbio.com/

Important dates

Future events
There are no future events available.
Past events
AGM 27 June 2024 27/06/24
Final results 07 May 2024 07/05/24

General stock information

EPIC:
GENF
ISIN:
GB00BP2C3V08
Market cap:
£7.52 million
Shares in issue:
349.71 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Eric Leire
    Chief Executive Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.